Edema and the nephrotic syndrome;Ödeme und das nephrotische syndrom

Therapeutische Umschau

Volumn 61, Issue 11, 2004, Pages 655-660

  Klein, M ^a   Henschkowski, J ^a   Yu, Z ^a   Vogt, Bruno ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; DIURETIC AGENT; SODIUM;

ANTIBIOTIC THERAPY; DISEASE SEVERITY; EDEMA; EXTRACELLULAR SPACE; GLOMERULONEPHRITIS; GLOMERULOPATHY; HUMAN; HYPOALBUMINEMIA; INFECTION RISK; INTERSTITIAL FLUID; KIDNEY ARTERY STENOSIS; KIDNEY BLOOD FLOW; KIDNEY PERFUSION; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; PLASMA VOLUME; PROTEINURIA; RARE DISEASE; REVIEW; SODIUM RETENTION; SYMPTOMATOLOGY; THROMBOSIS PREVENTION; ULTRAFILTRATION; VEIN THROMBOSIS; WATER RETENTION; XENOBIOTIC METABOLISM; ADULT; ARTICLE; BLOOD; CHILD; EXTRACELLULAR FLUID; FOCAL GLOMERULOSCLEROSIS; METABOLISM; RECURRENT DISEASE; RISK FACTOR;

ADULT; CHILD; EDEMA; EXTRACELLULAR FLUID; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; NEPHROTIC SYNDROME; PROTEINURIA; RECURRENCE; RENAL ARTERY OBSTRUCTION; RISK FACTORS; SODIUM;

EID: 8744315249     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: 10.1024/0040-5930.61.11.655     Document Type: Review

References (10)

1. Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis 1987; 10: 157-71.
2. Bradley SE, Tyson CJ. The «nephrotic syndrome». New Engl J Med 1948; 238: 223-27 and 260-66.
3. Feraille E, Vogt B, Rousselot M, Barlet-Bas C, Cheval L, Doucet A, Favre H. Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome. J Clin Invest 1993; 91: 1295-300.
4. Deschenes G, Feraille E, Doucet A. Mechanisms of oedema in nephrotic syndrome: old theories and new ideas. Nephrol Dial Transplant 2003; 18: 454-56.
5. Koomans HA. Pathophysiology of acute renal failure in idiopatic nephrotic syndrome. Nephrol Dial Transplant 2001; 16: 221-4.
6. Brater DC. Diuretic therapy. N Engl J Med 1998; 339: 387-95.
7. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-61.
8. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318: 1657-66.
9. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-78.
10. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002; 20: 125-30.